Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)

Autor: Sramila Aithal, Hendrik Tobias Arkenau, Muriel Siadak, Erica Stringer-Reasor, Mathilde Cancel, Erik Jakobsen, Erika Hamilton, Eva Harder Brix, Marco Colleoni, Cristiano Ferrario, Volkmar Mueller, Elisavet Paplomata, Amelia Zelnak, Frances M. Boyle, Elsa Curtit, S. Cold, Kendra DeBusk, Wentao Feng, Karen A. Gelmon, Margaret Block, Laurence Crouzet, Montserrat Muñoz-Mateu, Giuseppe Curigliano, Olwen Hahn, David Cameron, Andrew M Wardley, Nayyer Iqbal, Jorge Ramos, Teja Poosarla, Louis Fehrenbacher, Andrew Brenner

Publikováno v: Mueller, V, Wardley, A, Paplomata, E, Hamilton, E, Zelnak, A, Fehrenbacher, L, Jakobsen, E, Curtit, E, Boyle, F, Harder Brix, E, Brenner, A, Crouzet, L, Ferrario, C, Muñoz-Mateu, M, Arkenau, H T, Iqbal, N, Aithal, S, Block, M, Cold, S, Cancel, M, Hahn, O, Poosarla, T, Stringer-Reasor, E, Colleoni, M, Cameron, D, Curigliano, G, Siadak, M, DeBusk, K, Ramos, J, Feng, W & Gelmon, K 2021, ' Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial) ', European Journal of Cancer, vol. 153, pp. 223-233 . https://doi.org/10.1016/j.ejca.2021.05.025

Aims: In HER2CLIMB, tucatinib significantly improved progression-free and overall survival in patients with human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer. We evaluated the impact of tucatinib on health-related q

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7721317814dc77c16d150d44866186d
https://findresearcher.sdu.dk:8443/ws/files/184128629/Open_Access_Version.pdf

Abstract PD13-04: Impact of tucatinib on health-related quality of life in patients with HER2+ metastatic breast cancer with stable and active brain metastases

Autor: Teja Poosarla, Andrew M Wardley, Jorge Ramos, Karen A. Gelmon, Marie-Agnes By, Volkmar Mueller, Marco Colleoni, Giuseppe Curigliano, Sramila Aithal, Xuebei An, David Cameron, Erica Stringer-Reasor, Nayyer Iqbal, Søren Cold, Kendra DeBusk, Margaret Block, Laurence Crouzet, Elisavet Paplomata, Olwen Hahn, Muriel Siadak

Publikováno v: Cancer Research. 81:PD13-04

Background Patients (pts) with human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (MBC) who have brain metastases (BM) have limited treatment options and lower health-related quality of life (HRQoL) compared with pts w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bc59bc0252057d74228dc387db1f1aed
https://doi.org/10.1158/1538-7445.sabcs20-pd13-04

Effects on histologic subgroup, race, and BMI in 2,110 breast cancer patient: Results from single institution in Georgia

Autor: Joe Ensor, Elizabeth Mh Kim, Cynthia Lynch, Jonathan Ramey, Sramila Aithal, AT Johnson, Daniel W. Nixon, Ricardo H. Alvarez, K Rados, Rebecca Rollins, H Pabbathi, Rachel Pannell, Damien Hansra, John Edward McKnight, Eugene R Ahn

Publikováno v: Journal of Clinical Oncology. 37:e13112-e13112

e13112 Background: Disparities in breast cancer (BC) care still clearly exist among Whites (W) and African-Americans (AA) racial groups. These disparities resulting in higher mortality among AA compared to W. The objective of this analysis was to est

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::88445e7887ae7de8a0f5a81088e0e65e
https://doi.org/10.1200/jco.2019.37.15_suppl.e13112

Efficacy of olaparib monotherapy in patients (pts) with HER2-negative metastatic breast cancer (MBC) with germline BRCA mutation (gBRCAm) or lesional BRCA mutation (lBRCAm)

Autor: Siraj M. Ali, Daniel W. Nixon, Dennis L. Citrin, Mary Ninan, Cynthia Lynch, Sramila Aithal, Damien Hansra, Joe Ensor, Amber Moran, Amanda Woodward, Eleanor Meisner, Rebecca Rollins, Ricardo H. Alvarez, S. Zook, Eugene R Ahn, Maurie Markman

Publikováno v: Journal of Clinical Oncology. 36:1074-1074

1074Background: A recent Phase III study in MBC with gBRCAm, olaparib monotherapy provided a statistical significant and clinically meaningful PFS benefit compared to standard physician of choice t...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d531eb22dea669dcfd9449bb51d05a45
https://doi.org/10.1200/jco.2018.36.15_suppl.1074

Retinal Vein Thrombosis as the Presenting Symptom of Essential Thrombocythemia

Autor: Allan D. Novetsky, Harry Marshak, Norman A. Saffra, Sramila Aithal, Yi-Wu Huang, Jason Eli Tache

Publikováno v: The American Journal of the Medical Sciences. 329:139-140

Visual loss resulting from retinal vascular disorders can be the presenting sign of serious systemic disease. Associations between retinal vein thrombosis and other systemic disorders have been well documented, but a comprehensive literature search f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::724fbfd098c29f63ecbf4ea06674bc61
https://doi.org/10.1097/00000441-200503000-00005